Company Information

 

Healius Limited (ASX: HLS)

Healius Limited is a healthcare company. The Company’s segments include Pathology, Imaging and Other. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment provides imaging services from standalone imaging sites, hospitals and medical centers.

It has a network of pathology laboratories, collection centers and diagnostic imaging centers. It provides specialty diagnostic services to consumers and their referring practitioners. Its brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, Vetnostics, TML Vetnostics, Agilex Biolabs, Lumus Imaging, and others.

Its Pathology operates 100 medical laboratories and 2,000 patient collection centers across metropolitan, regional and remote Australia. IQ Pathology is a specialized dermatopathology laboratory that provides comprehensive dermatopathology services Australia wide.

 

Top Australian Brokers

 

REVENUE IN AUD (TTM)

1.69bn

NET INCOME IN AUD

-984.10m

Year on year Healius Ltd’s revenues fell -25.43% from 2.29bn to 1.71bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 307.90m to a loss of 367.80m.

 

Healius Limited (ASX: HLS) Live Chart

 

Healius Limited (ASX: HLS) Forecast

Based on 6 Wall Street analysts offering 12 month price targets for Healius Limited The average price target is AU$1.29 with a high forecast of AU$1.50 and a low forecast of AU$0.90. The average price target represents a -11.39% change from the last price of AU$1.46.

 

Latest ASX News

 

Healius Limited (ASX: HLS) Performance

 

Healius Limited (ASX: HLS) Fundamentals

 

Healius Limited (ASX: HLS) Competitors

 

Don’t Buy Just Yet

You will want to see this before you make any decisions.

Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.

Our experts picked out The 5 best ASX shares to buy in 2024.

We’re giving away this valuable research for FREE.

Click below to secure your copy